Imbruvica ibrutinib: Clinical trial data

Data from 16 relapsed/refractory CLL patients with prior allogeneic HSCT who received Imbruvica alone or in combination with Arzerra ofatumumab in 1 of 4 clinical trials showed that Imbruvica led to an ORR of 88%, including 2 complete responses, 9 partial responses (PR) and 3 PRs with lymphocytosis. Median follow-up was 23.3 months and median time on Imbruvica treatment was 18 months. Median duration of response, PFS and OS were not yet reached. The estimated 24-month PFS and OS rates were 76.6% and 75%, respectively. Imbruvica was well tolerated in the population. The study collected data from relapsed/refractory CLL patients with prior allogeneic HSCT who were enrolled in the Phase I/II PCYC-1102 and PCYC-1109 trials, the Phase II PCYC-1117 trial or the Phase III RESONATE (PCYC-1112) trial. Data were presented at the American Society for Blood and Marrow Transplantation meeting in San Diego. ...